A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Inclusion Criteria:

• All participants must have prior treatment with dupilumab meeting one of thefollowing conditions:

• Participants who stopped dupilumab treatment due to non-response, partialresponse, loss of efficacy must have been previously treated with dupilumab (atlabeled dose level) for at least 4 months.

• Participants who stopped dupilumab treatment due to intolerance or adverseevents (AEs) to the drug may enter the study with no required prior length ofdupilumab treatment.

• Participants who stopped dupilumab treatment due to cost or loss of access todupilumab (for example, insurance coverage) may enter the study with norequired prior length of dupilumab treatment.

• Participants who have chronic AD that has been present for ≥1 year before screening.

• Have EASI ≥16 at baseline

• Have IGA score ≥3 (Scale of 0 to 4) at baseline

• Have ≥10% body surface area (BSA) of AD involvement at baseline

• Have a history of inadequate response to treatment with topical medications; ordetermination that topical treatments are otherwise medically inadvisable.

• Adolescents body weight must be ≥40 kg at baseline.

Exclusion Criteria:

• History of human immunodeficiency virus (HIV) infection or positive HIV serology atscreening.

• Have a current infection or chronic infection with hepatitis B virus (HBV) atscreening (that is, positive for hepatitis B surface antigen and/or polymerase chainreaction positive for HBV DNA

• Have a current infection with hepatitis C virus (HCV) at screening (that is,positive for HCV RNA

• Have an uncontrolled chronic disease that might require multiple intermittent usesof oral corticosteroids at screening, as defined by the investigator.

• Have uncontrolled asthma that

• might require bursts of oral or systemic corticosteroids, or

• required the following due to ≥1 exacerbations within 12 months before baseline

• systemic (oral and/or parenteral) corticosteroid treatment, or

• hospitalization for >24 hours.

• Have known liver cirrhosis and/or chronic hepatitis of any etiology.

• Had Dupilumab treatment within 4 weeks prior to baseline

• Had prior treatment with tralokinumab.

• Treatment with topical agents: corticosteroids, calcineurin inhibitors, Janus Kinase (JAK) inhibitors, or phosphodiesterase-4 inhibitors, such as crisaborole within 2weeks prior to baseline

• Treatment with any of the following agents within 4 weeks prior to the baseline

• systemic immunosuppressive or immunomodulating drugs (e.g., systemiccorticosteroids, cyclosporine, mycophenolate mofetil, IFN-gamma, azathioprine,methotrexate, and other immunosuppressants)

• small molecules (e.g. JAK inhibitors)

• phototherapy and photochemotherapy for AD